Sun Pharmaceutical Industries is currently trading at Rs. 622.70, up by 8.30 points or 1.35% from its previous closing of Rs. 614.40 on the BSE.
The scrip opened at Rs. 614.50 and has touched a high and low of Rs. 623.70 and Rs. 614.50 respectively. So far 35,000 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 898.00 on 23-Feb-2016 and a 52 week low of Rs. 572.40 on 09-Nov-2016.
Last one week high and low of the scrip stood at Rs. 651.95 and Rs. 613.00 respectively. The current market cap of the company is Rs. 1,49,254.00 crore.
The promoters holding in the company stood at 54.97%, while Institutions and Non-Institutions held 33.34% and 11.68% respectively.
Sun Pharmaceutical Industries plans to acquire a branded oncology product, Odomzo, from Novartis. The agreement has been signed between subsidiaries of both the companies and will close following anti-trust clearance and further closing conditions. The agreement has been signed for an upfront payment of $175 million and additional milestone payments.
Odomzo (Sonidegib) was approved by the USFDA in July 2015. Odomzo is a hedgehog pathway inhibitor indicated for the treatment of adult patients with locally advanced basal cell carcinoma (laBCC) that has recurred following surgery or radiation therapy, or those who are not candidates for surgery or radiation therapy.
Sun Pharma is the world's fifth largest specialty generic pharmaceutical company and India's top pharmaceutical company. A vertically integrated business, economies of scale and an extremely skilled team enable us to deliver quality products in a timely manner at affordable prices. It provides high-quality, affordable medicines trusted by customers and patients in over 150 countries across the world.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1487.45 |
| Dr. Reddys Lab | 5822.90 |
| Cipla | 1497.85 |
| Zydus Lifesciences | 1049.75 |
| Lupin | 1630.00 |
| View more.. | |
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Buy quality Stocks when they are available at reasonable prices and supported by an upward price trend and Sell when they are Overvalued using the Decizen Rating System. Covers 3500+ stocks
Download APP
